Two-year outcomes good for “treat and extend” AMD therapy

April 15, 2015

Using a treat-and-extend regimen in routine clinical practice for patients with neovascular age-related macular degeneration (AMD) achieves good visual outcomes and decreases treatments and clinic visits, according to a study in Ophthalmology.

Using a treat-and-extend regimen in routine clinical practice for patients with neovascular age-related macular degeneration (AMD) achieves good visual outcomes and decreases treatments and clinic visits, according to a study in Ophthalmology.

Researchers in Australia and Switzerland conducted a database observational study of 1198 eyes with neovascular AMD in 1011 patients, a cohort of the Fight Retinal Blindness observational registry. The treatment-naïve eyes received a treat-and-extend regimen of anti-vascular endothelial growth factor (VEGF) therapy (predominantly ranibizumab).

The 24-month outcome measures were change in visual acuity (VA) and number of anti-VEGF injections and visits.

The findings at 24 months:

• Mean VA increased from 56.5 letters (20/80+1) at initial visit to 61.8 (20/60+2) letters, a man increase of +5.3 logarithm of the minimum angle of resolution letters.

• Both the mean VA gains and the number of injections increased with successive years. Mean VA gains  increased from +2.7 letters for eyes commencing in 2007 (after a mean of 9.7 injections over 24 months), to +7.8 letters for eyes commencing in 2012 (after a mean of 14.2 injections over 24 months).

 

• 27% of eyes had VA >20/40 when starting treatment; that increased to 45% after 24 months.

• 13% of eyes had initial vision of <20/200; that remained unchanged (11%) at 24 months.

• 90.5% of the included avoided a vision loss of ≥15 letters.

• There was a mean of 14.8 clinic visits over 24 months. The overall mean of 13.0 injections was comprised of 7.5 injections in the first year and 5.5 in the second year.

Related Content:

News